Background {#Sec1}
==========

There were approximately 950,000 new stomach cancer cases and 720,000 deaths that occurred in 2012 worldwide \[[@CR1]\]. In general, China is one of the highest incidence countries worldwide \[[@CR1]\]. Gastric adenocarcinoma (GAC) accounts for approximately 90 % of all diagnosed stomach cancers. It was also one of the most frequent causes of cancer-related deaths. The 5-year survival rate is less than 5 % for GAC patients with distant metastasis, as well as is less than 60 % for patients with only localized malignancies \[[@CR2]\]. In China, the majority of patients diagnosed with GAC have advanced stages of disease and are unsuitable for curative surgery.

Tumor recurrence and metastasis are the most common cause of treatment failure. Tumor recurrence and metastasis involve in multiple steps with a high degree of complexity and require the contribution of many molecules. Metastasis-associated in colon cancer-1 (MACC1) is a gene which contributes to these processes. MACC1 was first identified in colon cancer in 2009 and was bound to the promoter of the mesenchymal-epithelial transition (MET) gene to control its transcriptional activity \[[@CR3], [@CR4]\]. In vitro, MACC1 may drive proliferation, migration, invasion, and dissemination \[[@CR5]\]; in vivo, it may regulate gene transcriptionally for metastasis, such as tyrosine kinase MET \[[@CR5]--[@CR7]\]. Furthermore, accumulating evidence has indicated that MACC1 should contribute to apoptosis and epithelial-mesenchymal transition (EMT) via hepatocyte growth factor/mesenchymal-epithelial transition (HGF/MET) pathways \[[@CR8]\]. MACC1 was also considered as a decisive driver for metastasis and tumorigenesis \[[@CR9]\]. MACC1 was also an independent prognostic factor for colon cancer \[[@CR3], [@CR5]\]. Now, more and more studies have demonstrated that MACC1 could also be a metastatic and prognostic factor for various human cancers, including pancreatic \[[@CR10]\], liver \[[@CR11]\], lung \[[@CR12]\], ovary \[[@CR13]\], breast \[[@CR14]\], gastric \[[@CR8]\], malignant glioma \[[@CR15]\], and cervical carcinoma \[[@CR16]\].

Kangai 1 (KAI1) was first identified as a suppressor of metastasis gene in prostate carcinoma \[[@CR17]\]. KAI1 protein which is located in human chromosome 11p11.2 is a member of the transmembrane 4 superfamily (TM4SF). KAI1 can regulate signal transduction both cells to cells and cells to extracellular matrix (ECM) \[[@CR18]\] and involve in some fundamental biological processes such as fusion, migration, adhesion, fertilization, differentiation, and invasion \[[@CR19], [@CR20]\]. Accumulating evidence has demonstrated that decreased or lost KAI1 expression should associate with metastasis and prognosis in various tumors, including laryngeal carcinoma \[[@CR20]\], prostate carcinoma \[[@CR19], [@CR21]\], breast carcinoma \[[@CR22]\], lung carcinoma \[[@CR23]\], gastric carcinoma \[[@CR24]\], colon carcinoma \[[@CR25]\], and hepatocellular carcinoma \[[@CR26]\].

The involvement of MACC1 and KAI1 in the recurrence and metastasis of GAC suggests that they should be valuable biomarkers for measuring cancer progression and developing higher accurately therapeutic targets. To our knowledge, a correlation between MACC1 and KAI1 in GAC has not yet been reported. In this study, we detected the association between MACC1 and KAI1 expression in patient cancer tissues as well as compared their expression with clinicopathology, metastasis, and prognosis of GAC.

Methods {#Sec2}
=======

Biopsy specimens {#Sec3}
----------------

GAC tissues and adjacent noncancerous gastric tissues were collected at the Department of Pathology of the First Affiliated Hospital of Bengbu Medical College, from January 2008 to December 2010. Patients who had received preoperative chemo- or radio-therapy were excluded. All tissue specimens were obtained with patient consent, and the research was approved by the ethical committee of Bengbu Medical College and conducted in accordance with the ethical guidelines of the Declaration of Helsinki. The adjacent noncancerous gastric tissues were removed from the same patient, avoiding necrotic tissue, and from surrounding gastric tissue at least 5 cm away from the carcinoma edge. The research group consisted of 325 patients, 214 males and 111 females, aged from 26 to 78 years; the average age was 57.7 ± 10.9 years. All patients who had completely clinical, pathological, and follow-up (at 8-month intervals by phone, mail, or email) data were sporadic cases. Overall survival (OS) time was collected from surgery to death or December 2015 (mean OS time 42.0 months; range 8--95 months). Tumor node metastasis stage was evaluated according to the 7th edition of the American Joint Committee on Cancer (AJCC). Grade of tumor differentiation was according to the World Health Organization (WHO) standard.

Please contact author for data requests.

Immunohistochemistry {#Sec4}
--------------------

All GAC and corresponding normal gastric tissues were fixed in 10 % buffered formalin and embedded in paraffin. Then continuous 4-μm-thick tissue sections were cut. Subsequently, all sections were deparaffinized and dehydrated with xylene, graded ethanol, and washed for 10 min in PBS (pH 7.2). Immunohistochemistry was performed according to the Elivision Plus detection kit instructions (Lab Vision, USA). Endogenous peroxidase activity was blocked by incubation of sections in methanol containing 3 % H~2~O~2~ for 10 min at room temperature, then placed in citrate buffer (pH 6.0) and heated to 95 °C for 30 min for antigen repair. After several washes in PBS, the sections were quenched with goat serum for 20 min at room temperature, then incubated with rabbit polyclonal antibody against human MACC1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or mouse monoclonal antibody against human KAI1 (Abcam, Cambridge, MA, USA) for 1 h at 37 °C. All sections were counterstained with hematoxylin, dehydrated, air-dried, and mounted. Negative controls were prepared by deleting primary antibodies from the staining procedure. MACC1-positive staining was mainly confined in the cytoplasm of cancer cells, and KAI1-positive staining was mainly confined in the membrane and cytoplasm of cancer cells.

Evaluation of staining {#Sec5}
----------------------

Staining results were evaluated by two experienced pathologists who were blind to the clinical data and assessed by semi-quantitative scores. Because of intratumoral heterogeneity of antibody expression, we randomly chose ten visual fields from different areas of each section of GAC. If there was a disagreement, the pathologists would reexamine the immunostaining and reach a consensus \[[@CR27]--[@CR29]\]. To assess MACC1 and KAI1 expression, both the extent and intensity of immunostaining were thought \[[@CR27]\]. The staining extent score was graded as follows: none, 0; weak, 1; moderate, 2; and strong, 3. The intensity of positive staining was graded as follows: \<10 %, 1; 11--50 %, 2; 51--75 %, 3; and \>75 %, 4. Then the score was determined by multiplying the extent and intensity of immunostaining to reach a range of scores from 0 to 12. For tumors that were positive for both MACC1 and KAI1, an average of the final of each sample was taken. Immunostaining was thought positive when the score was ≥3.

Statistical analysis {#Sec6}
--------------------

Relationship between either MACC1- or KAI1 protein expression and clinicopathological parameters were compared using Fisher's exact test or chi-square test. The correlation between MACC1 and KAI1 expression was compared using Spearman's coefficient test. The effects of MACC1 and KAI1 expression on OS time were determined using Kaplan-Meier method for univariate analysis. Independent prognostic indicators were determined using the Cox regression model for multivariate analysis. The association between the positive expression of either MACC1 or KAI1 and clinicopathological parameters was determined using SPSS 19.0 software for Windows (Chicago, IL). A value of *P* \< 0.05 was determined as statistically significant.

Results {#Sec7}
=======

All GAC patient clinicopathological characteristics could be seen in Table [1](#Tab1){ref-type="table"}.Table 1Patients characteristicsPatients characteristicsFrequency (*n*)Percentage (%)Gender Male21465.8 Female11134.2Ages \<5814043.1 ≥5818556.9Gross type Polypoid3711.4 Ulcerative22067.7 Invasive6820.9Location Antrum16350.2 Cardia11836.3 Pylorus4413.5Size  *D* \< 4.0 cm7523.1 4.0 cm ≤ *D* \< 8.0 cm21164.9 8.0 cm ≤ *D*3912.0Depth of invasion Submucosa216.5 Subserosa10030.8 Visceral peritoneum18456.6 Adjacent structures206.2Tumor grade Well4714.5 Moderate20462.8 Poor7422.8Lymph node metastasis No17854.8 Yes14745.2TNM stage I and II15347.1 III and IV17252.9

Expression of MACC1 and KAI1 in GAC and their association with clinicopathology {#Sec8}
-------------------------------------------------------------------------------

To assess the contributions of MACC1 and KAI1 to GAC, their expression levels were evaluated in both GAC and normal gastric tissue slides using immunohistochemistry. MACC1-positive staining was mainly confined in the cytoplasm of cancer cells, and KAI1-positive staining was mainly confined in the membrane and cytoplasm of cancer cells. These data were compared to clinicopathological characteristics. The positive rate of MACC1 protein expression was 60.3 % (196/325) in GAC tissues and 9.2 % (30/325) in normal gastric tissues (Fig. [1a](#Fig1){ref-type="fig"}, [b](#Fig1){ref-type="fig"}), and this difference was shown to be statistically significant (*P* \< 0.01). There were also significant differences between the expression of MACC1 and tumor grade (*P* = 0.009), size of tumor (*P* = 0.009), invasion of depth (*P* \< 0.001), lymph node metastasis (LNM) (*P* \< 0.001), and tumor-node-metastasis (TNM) (*P* \< 0.001). In contrast, there were no associations detected between MACC1 expression and patient age (*P* = 0.295), gender (*P* = 0.482), location (*P* = 0.072), and gross type (*P* = 0.108).Fig. 1Representative results of MACC1 and KAI1 in gastric adenocarcinoma and control group. **a** Control gastric epithelial cells not expressing MACC1. **b** MACC1 predominantly localized in the cytoplasm in moderate grade of gastric carcinoma (MACC1 ×400). **c** Control gastric epithelial cells expressing KAI1 in the membrane and cytoplasm. **d** Moderate grade of gastric carcinoma cells not expressing KAI1 (KAI1 ×400) (**b** and **d** are the same GAC patient's slice)

In contrast to MACC1 expression, the expression of KAI1 was significantly lower in GAC than in control tissues, with positive rates of 41.2 % (134/325) and 92.3 % (300/325), respectively (*P* \< 0.01) (Fig. [1c](#Fig1){ref-type="fig"}, [d](#Fig1){ref-type="fig"}). There were also negative associations between expression of KAI1 in GAC and tumor grades (*P* = 0.045), invasion of depth (*P* \< 0.001), lymph node metastasis (*P* = 0.016), and TNM stage (*P* \< 0.001). There were no relationships detected between KAI1 expression and patient age (*P* = 0.079), gender (*P* = 0.065), size of tumor (*P* = 0.354), location (*P* = 0.372), and gross type (*P* = 0.965) (Table [2](#Tab2){ref-type="table"}). Spearman correlation coefficient analysis demonstrated a negative correlation between the expression of MACC1 and KAI1 (r = −0.240, *P* \< 0.001) (Table [2](#Tab2){ref-type="table"}).Table 2The association between the expression of MACC1 or KAI1 and clinicopathological characteristics in gastric adenocarcinomaVariableMACC1*P* valueKAI1*P* valueNegativePositiveNegativePositiveGender0.4820.065 Male8213211896 Female47647338Ages0.2950.079 \<5851899050 ≥587810710184Gross type0.1080.965 Polypoid20172116 Ulcerative8014013090 Invasive29394028Location0.0720.372 Antrum64999271 Cardia41776949 Pylorus24203014Size0.0090.354  *D* \< 4.0 cm35404233 4.0 cm ≤ *D* \< 8.0 cm8712412289 8.0 cm ≤ *D*7322712Depth of invasion\<0.001\<0.001 Submucosa138912 Subserosa53474357 Visceral peritoneum5912512262 Adjacent structures416173Tumor grade0.0090.045 Well20272126 Moderate9111312084 Poor18565024Lymph node metastasis\<0.0010.016 No93859484 Yes361119750TNM stage\<0.001\<0.001 I and II96577182 III and IV3313912052 KAI1^a^\<0.001 Negative57134 Positive7262^a^Negative relationship (*r* = −0.240, *P* \< 0.001)

Univariate analysis {#Sec9}
-------------------

Follow-up data indicated that overall survival time was significantly decreased in GAC patients with positive expression of MACC1 (32.7 months) compared to those who were MACC1-negative (56.1 months) (log-rank = 46.375, *P* \< 0.001) (Fig. [2a](#Fig2){ref-type="fig"}). On the contrast, the OS time of KAI1-positive patients (52.6 months) was significantly longer than those tumors which were negative (34.5 months) (log-rank = 25.422, *P* \< 0.001) (Fig. [2b](#Fig2){ref-type="fig"}). In the univariate analysis, OS time was significantly related to clinicopathological characteristics, such as tumor diameter (*P* = 0.033, log-rank = 6.844), invasion of depth (*P* \< 0.001, log-rank = 26.806), LNM (*P* \< 0.001, log-rank = 75.925), and TNM stage (*P* \< 0.001, log-rank = 158.587) (Table [3](#Tab3){ref-type="table"}).Fig. 2Kaplan-Meier survival analysis by MACC1 and KAI1 status. The *y*-axis represents the percentage of patient; the *x*-axis, their survival in months. The *green line* represents patients with positive expression of MACC1 (**a**) or KAI1 (**b**) with a trend of worse or better survival time than the *blue line* representing the negative MACC1 group or KAI1 group (*P* \< 0.001). Mean survival time was 32.7 months for the positive expression of the MACC1 group and 56.1 months for the negative MACC1 group. Mean survival time was 52.6 months for the positive expression of the KAI1 group and 34.5 months for the negative KAI1 group (*n* = 325) Table 3Results of univariate analyses of overall survival (OS) timeVariable*n*Mean OS (months)Log-rank*P* valueMACC146.375\<0.001 Negative12956.1 ± 22.3 Positive19632.7 ± 24.5KAI125.422\<0.001 Negative19134.5 ± 25.6 Positive13452.6 ± 23.4Gender0.1870.666 Male21442.5 ± 26.2 Female11141.0 ± 26.5Ages0.4200.517  \< 5814041.6 ± 27.2  ≥ 5818542.3 ± 25.6Gross type0.5410.763 Polypoid3746.3 ± 26.8 Ulcerative22041.7 ± 26.1 Invasive6840.5 ± 26.5Location5.5360.063 Antrum16341.4 ± 26.5 Cardia11844.3 ± 26.7 Pylorus4437.9 ± 23.8Size6.8440.033  *D* \< 4.0 cm7549.8 ± 27.8 4.0 cm ≤ *D* \< 8.0 cm21140.0 ± 25.5 8.0 cm ≤ *D*3938.4 ± 25.0Depth of invasion26.806\<0.001 Submucosa2164.1 ± 16.7 Subserosa10050.6 ± 27.1 Visceral peritoneum18435.8 ± 24.3 Adjacent structures2032.5 ± 23.6Tumor grade2.5760.276 Well4747.0 ± 32.6 Moderate20440.8 ± 24.3 Poor7442.0 ± 26.9LNM75.925\<0.001 No17853.4 ± 24.1 Yes14728.2 ± 21.8TNM stage158.587\<0.001 I and II15360.9 ± 18.1 III and IV17225.2 ± 20.2

Multivariate analysis {#Sec10}
---------------------

Multivariate analysis demonstrated that positive expression of either MACC1 or KAI1, as well as TNM stage, was an independent prognostic indicator for GAC (Table [4](#Tab4){ref-type="table"}).Table 4Results of multivariate analyses of overall survival (OS) timeCovariateBSE*P*HR95 % CITNM stage1.2770.181\<0.0013.5852.513--5.112MACC10.3850.1500.0101.4701.096--1.972KAI1−0.4340.1410.0020.6480.492--0.854

Discussion {#Sec11}
==========

Gastric adenocarcinoma (GAC) is a highly heterogeneous tumor. This heterogeneity may affect the reproducibility of biomarker evaluation \[[@CR5], [@CR30]\]. So, thorough investigation of the metastatic and prognostic values of a candidate biomarker is thus required to ensure validity. In our study, we investigated MACC1 expression in GAC and matched normal tissues from 325 patients and compared it to clinicopathological characteristics. We found that MACC1 expression was significantly higher in GAC tissues than that in the control tissues. Furthermore, MACC1 expression was positively correlated with tumor size, grade, invasion of depth, LNM, and TNM stage. Our results were consistent with those of previous studies in GAC \[[@CR8], [@CR31]--[@CR33]\] demonstrating that MACC1 should be useful as a clinical candidate biomarker of GAC.

KAI1, a cell membrane protein that binds to ECM or adhesion proteins \[[@CR34], [@CR35]\], is widely considered as a suppresser gene of metastasis in many cancers \[[@CR19]--[@CR26]\]. KAI1 has been correlated with carcinogenesis \[[@CR20]\] and showed to predict a poor metastasis and prognosis \[[@CR19]--[@CR26]\]. In this study, we also found that KAI1 expression was significantly related to tumor grade, invasion of depth, LNM, and TNM stage. In addition, Kaplan-Meier survival analysis indicated that GAC patients with positive KAI1 expression had significantly increased survival time compared to those with negative KAI1. These results indicated that KAI1 should play a key role in tumorigenesis, invasion, metastasis, and prognosis of GAC. Several other immunohistochemical studies that investigated the metastatic and prognostic significance of KAI1 in GAC patients obtained similar results \[[@CR24], [@CR36], [@CR37]\]. Thus, our results supported the conception that KAI1 should be a credible biomarker of GAC, especially for predicting metastasis and prognosis of cancers.

Metastasis and recurrence are the most common reasons of cancer-related deaths in GAC. TNM staging system is well-known as the guide for devising therapeutic strategies for patients with GAC. However, the TNM staging system cannot provide comprehensive information about the biological behavior of the cancer. Thus, it is urgent to seek novel and effective metastatic and prognostic biomarkers to predict biological behavior (metastasis and recurrence) in GAC patients. In our study, multivariate Cox model analysis showed that the positive expression of either MACC1 or KAI1, as well as TNM stage, was an independent prognostic indicator for patients with GAC.

In our study, we found that MACC1 expression was negatively correlated with KAI1 expression. Furthermore, we also found that there was a negative correlation between the high expression of MACC1 and low expression of KAI1 in the same GAC patient. Abnormal (decreased or lost) expression of KAI1 may be involved in the initiation, development, invasion, metastasis, and recurrence of GAC through lost of function of tumor suppressor gene or suppressor gene of tumor metastasis. Indeed, KAI1, as a suppressor of tumor metastasis, could inhibit β-catenin tyrosine phosphorylation and stabilize E-cadherin-β-catenin complexes to suppress tumor metastasis \[[@CR38]\]. In addition, KAI1 could inhibit the process of β-catenin-mediated EMT to prevent tumor angiogenesis and lymphangiogenesis \[[@CR39]\]. Meanwhile, MACC1 could be bound to the promoter of the MET gene and activate the HGF/MET signaling pathway to promote cancer cell proliferation, invasion, and metastasis \[[@CR3], [@CR4]\]. Furthermore, it could promote angiogenesis and lymphangiogenesis to lead to cancer cell invasion and metastasis \[[@CR40], [@CR41]\]. Moreover, KAI1 is able to be bind to c-MET to form a complex or quench the activation of HGF, thus preventing the activation of MACC1 to inhibit the migration of tumor cells \[[@CR42], [@CR43]\]. Decreased or lost expression of KAI1 might lose inhibiting the activation of MACC1, angiogenesis and lymphangiogenesis, and stabilization of E-cadherin-β-catenin complexes to promote cancer cell invasion and metastasis. At the same time, abnormal expression of MACC1 could further promote cancer cell invasion and metastasis. However, the methodology of subjects in our study was relatively simple; further studies with more methodologies (such as assessing the effect of target molecules on biological properties in vitro and in vivo models) are needed to verify the present observation.

Conclusions {#Sec12}
===========

Our findings indicate that abnormal expression of MACC1 and KAI1 should play key roles in the development of GAC. The combined detection of MACC1 and KAI1 may be valuable as biomarkers for metastasis and thereby prognosis for patients with GAC.
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